OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Clinical Immunology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Natural history of COVID-19 and therapeutic options	98
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis	91
A comparative review of immunoassays for COVID-19 detection	76
Circulating Calprotectin as a Biomarker of COVID-19 Severity	76
The role of IL-6 and IL-6 blockade in COVID-19	69
Breast implant illness: scientific evidence of its existence	63
SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives	58
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives	43
An update on VEXAS syndrome	42
Epidemiology of rheumatoid arthritis: genetic and environmental influences	41
The infection risks of JAK inhibition	40
The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review	35
Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion	35
The emerging role of type 2 inflammation in asthma	35
Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis	30
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection	28
Generalized pustular psoriasis: current management status and unmet medical needs in Japan	28
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults	28
Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus	27
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation	25
Mechanical ventilation in Guillain–Barré syndrome	25
Emerging therapy options for IgG4-related disease	24
Emerging therapies for ulcerative colitis	24
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials	24
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events	24

Gut microbiota in Celiac Disease: microbes, metabolites, pathways and therapeutics	23
Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology	23
The pathogenic oral–gut–liver axis: new understandings and clinical implications	22
Rheumatoid arthritis related interstitial lung disease	22
The role of PCSK9 in inflammation, immunity, and autoimmune diseases	22
A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progressi	22
Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis	21
Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits	20
Is post-COVID syndrome an autoimmune disease?	20
Autoimmunity in common variable immunodeficiency: a systematic review and meta-analysis	20
Comorbid allergic rhinitis and asthma: important clinical considerations	20
Autoimmune hemolytic anemia: causes and consequences	20
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis	19
An immunologist’s guide to immunosenescence and its treatment	19
Impact of resolvin mediators in the immunopathology of diabetes and wound healing	18
Therapeutic targeting of the IL-13 pathway in skin inflammation	17
Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making	16
Chimeric antigen receptor T-cell therapy for melanoma	16
Gut inflammation in CVID: causes and consequences	16
The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives	16
Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review	16
Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives	16
Tofacitinib for the treatment of active ankylosing spondylitis in adults	16
Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis	15
An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications	15
Biomarkers of chronic spontaneous urticaria and their clinical implications	15
Clinical relevance of T follicular helper cells in systemic lupus erythematosus	15
Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions	15
Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review	14
Myosin light chain kinase regulates intestinal permeability of mucosal homeostasis in Crohn’s disease	14
Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic	13
Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis	13
Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS)	13
Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights	13
The pathophysiology of MASLD: an immunometabolic perspective	13
New frontiers in precision medicine for Sjogren’s syndrome	13
Glucocorticoids in rheumatoid arthritis still on first line: the reasons	13
Heterogeneity in myasthenia gravis: considerations for disease management	13
Oral immunotherapy for food allergy in children: is it worth it?	13
Recent issues in JAK inhibitor safety: perspective for the clinician	13
The clinical implications of the microbiome in the development of allergy diseases	13
Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis	13
Gut immune homeostasis: the immunomodulatory role of Bacillus clausii, from basic to clinical evidence	13
Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm	13
Hematopoietic stem cell transplantation in systemic autoinflammatory diseases - the first one hundred transplanted patients	12
Convalescent plasma and hyperimmune globulin therapy in COVID-19	12
BRAF inhibitors and their immunological effects in malignant melanoma	12
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment	12
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis	12
Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation	12

Avacopan for the treatment of ANCA-associated vasculitis	12
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab	12
Diagnosis and treatment of non-allergic rhinitis: focus on immunologic mechanisms	11
The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection	11
Palindromic rheumatism: a unique and enigmatic entity with a complex relationship with rheumatoid arthritis	11
Recent insights into the pathogenesis of autoimmune hypophysitis	11
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection	11
The GLP-1 receptor in airway inflammation in asthma: a promising novel target?	11
Autism spectrum disorders and natural killer cells: a review on pathogenesis and treatment	11
Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives	11
IgG4-related disease: advances in pathophysiology and treatment	11
Challenges in uncontrolled asthma in pediatrics: important considerations for the clinician	11
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic	11
Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2	10
Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus	10
Serum exosomal long noncoding RNA nuclear-enriched abundant transcript 1 predicts 90-day mortality in acute-on-chronic hepatitis B liver failure	10
Comparing available JAK inhibitors for treating patients with psoriasis	10
Mast cell activation: beyond histamine and tryptase	10
The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis	9
Management and treatment optimization of patients with mild to moderate ulcerative colitis	9
Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis	9
DEL-1: a potential therapeutic target in inflammatory and autoimmune disease?	9
Diagnosis and clinical management of Wiskott–Aldrich syndrome: current and emerging techniques	9
Model-based computational precision medicine to develop combination therapies for autoimmune diseases	9
Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics	9
Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients	9
Predicting lupus flares: epidemiological and disease related risk factors	9
Temporal trends in anaphylaxis ED visits over the last decade and the effect of COVID-19 pandemic on these trends	8
Perspectives for immunotherapy in noninfectious immune mediated uveitis	8
The suitability of treating atopic dermatitis with Janus kinase inhibitors	8
Current treatment options and long-term outcomes in patients with eosinophilic esophagitis	8
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial	8
An updated review on Mendelian susceptibility to mycobacterial diseases– a silver jubilee celebration of its first genetic diagnosis	8
Regulation of crystal induced inflammation: current understandings and clinical implications	8
TL1A as a therapeutic target in inflammatory bowel disease	8
S. aureus and IgE-mediated diseases: pilot or copilot? A narrative review	8
Novel insights into the pathogenesis of virus-induced ARDS: review on the central role of the epithelial-endothelial barrier	8
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives	8
Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy	8
Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets	8
Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives	8
Lymphocytes subsets in correlation with clinical profile in CVID patients without monogenic defects	8
Comparing treatment options for large vessel vasculitis	8
Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective	8
The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders	8
Rationale for IL-37 as a novel therapeutic agent in inflammation	8
Managing puerperium in patients with systemic autoimmune diseases: an update	7
Type I interferon detection in autoimmune diseases: challenges and clinical applications	7
Chronic rhinosinusitis disease control: a review of the history and the evidence	7
Cytokine alterations in psoriasis: an updated review	7
The importance of transition from pediatric to adult rheumatology care in juvenile idiopathic arthritis	7
Tackling medical misinformation in allergy and immunology practice	7
Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus	7
Current status and prospects for the diagnosis of pemphigus vulgaris	7
TYK2 inhibition: changing the treatment landscape for psoriasis?	7
Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis	7
Antiphospholipid syndrome: the need for new international classification criteria	7
Novel therapeutic approaches for cutaneous T cell lymphomas	7
Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis	7
Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29^th EADV virtual congress, 29-31 October 2020	7
Combination immunotherapy for pancreatic cancer: challenges and future considerations	7
Peanut allergy: risk factors, immune mechanisms, and best practices for oral immunotherapy success	7
Treatment strategies, including antibiotics, to target the immune component of rosacea	7
Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis	7
A review of disease burden and clinical management for generalized pustular psoriasis in China	7